-
公开(公告)号：US5869035A
公开(公告)日：1999-02-09
申请号：US748344
申请日：1996-11-13
申请人： Charles J. Link, Jr. , John P. Levy
发明人： Charles J. Link, Jr. , John P. Levy
IPC分类号： A61K38/00 , A61K48/00 , A61P35/00 , C12N9/10 , A01N43/04 , A01N63/00 , A61K39/00 , C12N15/00
CPC分类号： C12N9/1051 , C12Y204/01228 , A61K38/00 , A61K48/00 , C12N2799/028
摘要： The invention discloses methods and compositions for killing tumor cells in animals. Through transfer techniques, cancer cells are engineered to express an epitope which is targeted by natural antibodies causing complement destruction of transformed tumor cells that is typically associated with hyperacute xenograft rejection.
摘要翻译： 本发明公开了杀死动物肿瘤细胞的方法和组合物。 通过转移技术，癌细胞被工程化以表达由天然抗体靶向的表位，导致通常与超急性异种移植排斥相关的转化的肿瘤细胞的补体破坏。
-
2.发明授权Vehicles for stable transfer of green fluorescent protein gene and methods of use for same 失效用于稳定转移绿色荧光蛋白基因的载体及其使用方法公开(公告)号：US06541197B2
公开(公告)日：2003-04-01
申请号：US08786531
申请日：1997-01-21
IPC分类号： C12Q170
CPC分类号： C12N15/86 , C12N2740/13043 , C12Q1/6897
摘要： The present invention describes an efficient retroviral or viral based method that allows easy and quick identification of gene transfer in living, transduced mammalian cells. Retroviral and viral vector producer cells were generated containing a gene for an improved humanized red-shifted, Green Fluorescent Protein (hRGFP) which increases the resulting fluorescence yield after excitation. This humanized, red-shifted GFP (hRGFP) gene was cloned into several vectors and transfected into various packaging cell lines to produce vibrant green fluorescence after excitation with blue light at 450-490 nm. These vectors represent a substantial advance over currently available gene transfer marking systems or wild-type GFP marker systems none of which have been stably transfected into cells.
摘要翻译： 本发明描述了一种有效的基于逆转录病毒或病毒的方法，其允许容易且快速地鉴定生物，转导的哺乳动物细胞中的基因转移。 产生逆转录病毒和病毒载体生产细胞，其包含用于改善的人源化红移绿色荧光蛋白（hRGFP）的基因，其增加激发后产生的荧光产率。 将这种人源化的红移GFP（hRGFP）基因克隆到几个载体中并转染到各种包装细胞系中，以在450-490nm的蓝光激发后产生鲜艳的绿色荧光。 这些载体代表了目前可用的基因转移标记系统或野生型GFP标记系统的实质进展，其中没有一个已经稳定转染到细胞中。
-
公开(公告)号：US07029665B2
公开(公告)日：2006-04-18
申请号：US10022127
申请日：2001-10-30
CPC分类号： H04B10/2504 , A61K48/00 , C12N9/22 , C12N15/11 , C12N2799/028
摘要： Novel synthetic suppressor tRNA have been provided which provide read-through of internal nonsense mutations, or which can site-specifically alter translation of transcribed sequences. Uses of the same are also provided in genetic engineering protocols including gene therapy treatment of diseases such as Xeroderma pigmentosum.
摘要翻译： 已经提供了新的合成抑制基因tRNA，其提供了内部无义突变的阅读，或者可以特异性地改变转录序列的翻译。 在遗传工程方案中还提供了其用途，包括染色剂如色素木病等基因治疗治疗。
-
4.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyl transferase 有权使用表达α（1,3） - 半乳糖基转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US07763461B2
公开(公告)日：2010-07-27
申请号：US11533184
申请日：2006-09-19
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用增强了抗原呈递细胞对调理肿瘤细胞的摄取，这导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
公开(公告)号：US5843459A
公开(公告)日：1998-12-01
申请号：US587725
申请日：1996-01-19
申请人： Suming Wang , Charles J. Link, Jr.
发明人： Suming Wang , Charles J. Link, Jr.
IPC分类号： C12N15/869 , C12Q1/70 , A61K39/245
CPC分类号： C12N15/86 , C12N2710/16643
摘要： Disclosed herein is the method for dramatically reducing cytotoxicity of viral vectors such as Herpes simplex viral while retaining gene expression. The method of the invention virtually eliminates the concern of possible recombination during virus propagation and contamination of wild-type virus and virus stock. The invention comprises use of photochemical crosslinking causing differential inactivation of viruses.
摘要翻译： 本文公开了在保留基因表达的同时显着降低病毒载体如单纯疱疹病毒的细胞毒性的方法。 本发明的方法实际上消除了在病毒繁殖和野生型病毒和病毒原液的污染期间可能的重组的担忧。 本发明包括使用光化学交联引起病毒的差异失活。
-
6.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase 有权使用表达α（1,3） - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US08535658B2
公开(公告)日：2013-09-17
申请号：US12878756
申请日：2010-09-09
IPC分类号： A61K48/00 , A61K39/39 , A61K31/70 , A61K39/395
CPC分类号： A61K39/395 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
公开(公告)号：US07125549B2
公开(公告)日：2006-10-24
申请号：US10297099
申请日：2001-05-31
IPC分类号： C12N15/63 , C12N15/64 , C12N15/861 , C12N15/867 , C12N15/869
CPC分类号： C12N15/86 , A61K38/00 , A61K48/00 , C12N7/00 , C12N2710/10343
摘要： The invention includes a viral vector method and composition comprising transcomplementary replication incompetent viral vectors, preferably adenoviral vectors, which are cotransformed to a recipient cell. The two vectors complement each other and thus allow viral replication, in a synergistic combination which enhances both gene delivery and gene expression of genetic sequences contained within the vector.
-
8.发明授权Radiation enhanced therapy for tumors expressing a gene for viral thymidine kinase in the presence of a 5-halogengated pyrimidine 失效在5-卤代嘧啶存在下，表达病毒胸苷激酶基因的肿瘤的放射增强疗法
公开(公告)号：US5985266A
公开(公告)日：1999-11-16
申请号：US903459
申请日：1997-07-30
CPC分类号： A61K48/00 , A61K41/0038
摘要： The present invention pertains to combination radio therapy of tumors and more specifically to pharmaceutical compositions, and methods of treatment by gene therapy designed to sensitize tumors in animals, notably humans, and render them more susceptible to radiation, thus significantly reducing the amount of radiation required to kill neoplastic cells while at the same time making the radiation far more tissue specific to the tumor site.
摘要翻译： 本发明涉及肿瘤的组合放射治疗，更具体地涉及药物组合物，以及通过设计用于使动物（特别是人）中的肿瘤敏感的基因治疗的治疗方法，并使它们更易于辐射，从而显着减少所需的辐射量 杀死肿瘤细胞，同时使辐射远远超过肿瘤部位特异性的组织。
-
公开(公告)号：US5830727A
公开(公告)日：1998-11-03
申请号：US578500
申请日：1995-12-26
申请人： Suming Wang , Charles J. Link, Jr.
发明人： Suming Wang , Charles J. Link, Jr.
IPC分类号： C12N15/869 , C12N15/389 , C12N5/10 , C12N15/86
CPC分类号： C12N15/86 , C12N2710/16643
摘要： A novel HSV mini viral vector is disclosed. The vector comprises HSV and EBV genes which allow it to remain in episomal state, to have very high transfection and infection, and to tolerate up to 140 kb of foreign DNA. Techniques and genetic constructs for producing the vectors, for constructing the vectors and transfection and infection to recipient cells are disclosed.
摘要翻译： 公开了一种新型HSV迷你病毒载体。 载体包含HSV和EBV基因，其允许其保持在附加状态，具有非常高的转染和感染，并且耐受高达140kb的外源DNA。 公开了用于产生载体的技术和遗传构建体，用于构建载体和转染和感染受体细胞。
-
10.发明授权Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase 有权使用表达α（1,3） - 半乳糖转移酶的同种异体肿瘤细胞的抗肿瘤疫苗接种公开(公告)号：US08551474B2
公开(公告)日：2013-10-08
申请号：US12890178
申请日：2010-09-24
CPC分类号： A61K35/13 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2267/0331 , A61K39/0011 , A61K2039/5152 , A61K2039/5156 , C12N5/10
摘要： The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.
摘要翻译： 本发明涉及用于引起肿瘤细胞选择性靶向和杀伤的方法和组合物。 通过离体基因治疗方案，肿瘤细胞被工程化以表达α（1,3）半乳糖基表位。 然后将细胞照射或以其它方式杀死并给予患者。 α-半乳糖基表位导致肿瘤细胞的调理作用，通过抗原呈递细胞增强调理肿瘤细胞的摄取，导致增强的肿瘤特异性抗原呈递。 因此，动物的免疫系统被刺激以产生将攻击和杀死存在于动物中的肿瘤细胞的肿瘤特异性细胞毒性细胞和抗体。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.026 秒)
